E. Mortensen

发表

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.

R. Hunt, R. Hunt, J. Bolognese, 2000, The American journal of medicine.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

C. Hawkey, L. Laine, J. Bolognese, 2001, Alimentary pharmacology & therapeutics.

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

J. Gómez-Reino, H. Valdez, K. Winthrop, 2015, Annals of the rheumatic diseases.

Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis

K. Rahimi, M. Javanbakht, S. Cook, 2019, PharmacoEconomics - Open.

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.

C. Hawkey, L. Laine, J. Bolognese, 2000, Arthritis and rheumatism.

Clinical trial: alvimopan for the management of post‐operative ileus after abdominal surgery: results of an international randomized, double‐blind, multicentre, placebo‐controlled clinical study

C. Seiler, M. Thompson-Fawcett, M. Büchler, 2008, Alimentary pharmacology & therapeutics.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

J. Wurzelmann, B. Lasko, E. Mortensen, 2011, The journal of pain : official journal of the American Pain Society.

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

H. Yamanaka, H. Valdez, K. Winthrop, 2014, Arthritis & rheumatology.

A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

J. Pénzes, E. Spierings, J. Wurzelmann, 2011, The journal of pain : official journal of the American Pain Society.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.

The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans

L. Jackson, T. Simon, E. Mortensen, 2001, Alimentary pharmacology & therapeutics.

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

L. Webster, B. Morlion, J. Peppin, 2008, PAIN®.